Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

New England Journal of Medicine

Volumn 328, Issue 14, 1993, Pages 1002-1006

  Fisher, Richard I ^a   Gaynor, Ellen R ^a   Dahlberg, Steve ^b   Oken, Martin M ^c   Grogan, Thomas M ^d   Mize, Evonne M ^b   Glick, John H ^e   Coltman, Charles A ^f   Miller, Thomas P ^d  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Virginia Piper Cancer Institute   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLLOW-UP STUDIES; HUMAN; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; METHOTREXATE; MIDDLE AGE; PREDNISONE; PROSPECTIVE STUDIES; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0027394689     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199304083281404     Document Type: Article

References (37)

1. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1:248-250
2. Schein PS, DeVita VT Jr, Hubbard S, Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85:417-422
3. Fisher RI, DeVita VT Jr, Johnson BL, Simon R, Young RC Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977; 63:177-182
4. Gaynor ER, Ultmann JE, Golomb HM, Sweet DL Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol 1985; 3:1596-1604
5. Coltman CA, Dahlberg S, Jones SE, et al. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Kimura K, ed. Cancer chemotherapy: challenges for the future. Tokyo, Japan: Excerpta Medica, 1988:194-202.
6. Coleman M Chemotherapy for large-cell lymphoma: optimism and caution. Ann Intern Med 1985; 103:140-142
7. Shipp MA, Harrington DP, Klatt MM, Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104:757-765
8. Fisher RI, DeVita VT Jr, Hubbard SM, Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 1984; 3:242-242
9. Klimo P, Connors JM MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102:596-602
10. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49:2112-2135
11. Longo DL, DeVita VT Jr, Duffey PL, Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9:25-38 [Erratum, J Clin Oncol 1991;9:710.]
12. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
13. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170
14. Cox DR Partial likelihood. Biometrika 1975; 62:269-276
15. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-220
16. Dana BW, Dahlberg S, Miller TP, m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol 1990; 8:1155-1162
17. Miller TP, Dahlberg S, Weick JK, Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol 1990; 8:1951-1958
18. Weick JK, Dahlberg S, Fisher RI, Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J Clin Oncol 1991; 9:748-753
19. Fisher RI, Hubbard SM, DeVita VT Jr, Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58:45-51
20. Dixon DO, Neilan B, Jones SE, Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4:295-305
21. Jagannath S, Velasquez WS, Tucker SL, Manning JT, McLaughlin P, Fuller LM Stage IV diffuse large-cell lymphoma: a long-term analysis. J Clin Oncol 1985; 3:39-47
22. Coiffier B, Lepage E Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in LNH-84 regimen. Blood 1989; 74:558-564
23. Danieu L, Wong G, Koziner B, Clarkson B Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46:5372-5379
24. Shipp M, Harrington D, Anderson J, Development of a predictive model for aggressive lymphomas: the international NHL Prognostic Factors Project. Proc Am Soc Clin Oncol 1992; 11:319-319 abstract.
25. Fisher RI, DeVita VT Jr, Hubbard SM, Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98:304-309
26. Skarin AT, Canellos GP, Rosenthal DS, Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1:91-98
27. Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97:190-195
28. Connors JM, Klimo P MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 1988; 25: Suppl 2: 41-46
29. Schneider AM, Straus DJ, Schluger AE, Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate-and some high-grade non-Hodgkin's lymphomas. J Clin Oncol 1990; 8:94-102
30. Lowenthal DA, White A, Koziner B, Straus DJ, Lee BJ, Clarkson BD MACOP-B for advanced diffuse intermediate and high grade non-Hodgkin's lymphoma (NHL): preliminary results of the Memorial Hospital experience. Proc Am Soc Clin Oncol 1987; 6:201-201 abstract.
31. Drug topics red book: annual pharmacists' reference. Oradell, N.J.: Medical Economics, 1992.
32. Gordon LI, Harrington D, Andersen J, Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342-1349
33. Montserrat E, Garcia-Conde J, Vinolas N, Estape J ProMACE-cytaBOM vs. CHOP in the treatment of unfavorable lymphomas: a randomized trial. Blood 1991; 78: Suppl 1: 127a-127a abstract.
34. Cooper IA, Ding JC, Matthews JP, A randomized comparison of MACOP-B and CHOP in intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1991; 10:271-271 abstract.
35. Carde P, Meerwaldt JH, van Glabbeke M, Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. Ann Oncol 1991; 2:431-435
36. Federico M, Moretti G, Gobbi PG, ProMACE-CytaBOM versus MACOP-B in intermediate and high grade NHL: preliminary results of a prospective randomized trial. Leukemia 1991; 5: Suppl 1: 95-101
37. Chisesi T, Santini G, Capnist G, ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG). Leukemia 1991; 5: Suppl 1: 107-111